e-Drug3D

1808

TRABECTEDIN

INN
TRABECTEDIN

cas 114899-77-3

CLASS

ANTINEOPLASTIC
ALKYLATING DRUG THAT BINDS GUANINE RESIDUES IN THE MINOR GROOVE OF DNA
TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA OR LEIOMYOSARCOMA

ROUTE (list)

INTRAVENOUS INJECTION

NATURAL MOLECULE (link)

ATC code

L01CX01

PK parameters

VD 5000 LITER
Cl 31.5 LITER / HOUR
PPB 97 PERCENT
t1/2 175 HOUR

Solubility

LOW SOLUBILITY IN WATER

Target

TARGET DNA

DrugCentral

Unknown

Download SDF file

Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinolin]-19-one, 5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (1'R,6R,6aR,7R,13S,14S,16R)-

Formula:
C39H43N3O11S

Calculated chemical properties:

MW 761.83
NB_atoms 54
XLogP 3.41
PSA 163.329
NB_HD 4
NB_HA 14
fsp3 0.49
Lipinski(0=no;1=yes) 0

FDA
NDA 207953 (label) INN (TRABECTEDIN) YONDELIS (JANSSEN PRODS) APPROVAL= AP YEAR= 2015
NDA 214837 (pdf not found) INN (TRABECTEDIN) TRABECTEDIN (NATCO PHARMA LTD) APPROVAL= TA YEAR= 2022